Table 7.
The mechanism of action of MIF inhibitors.
| MIF inhibitors | MIF inhibitory activity | Mechanism of action | Potential Binding sites |
|---|---|---|---|
| Ibudilast |
Kd = 55.1 µM Ki = 30.9 µM |
MIF tautomerase inhibitor Anti-inflammation Neuroprotection |
|
| Iguratimod | IC50 = 6.81 µM | MIF tautomerase inhibitor Anti-inflammation Immunomodulation Osteoprotection Anti-pulmonary fibrosis |
|
| ISO-1 | IC50 = 7-100 μM | MIF tautomerase inhibitor Anti-inflammation Neuroprotection |
LYS32, ILE64, ASN97, MET2, PRO1, TYR36, |
| Z-312 | IC50 = 0.55 µM | Covalent or slow, tight-binding MIF inhibitor Anti-inflammation |
|
| Z-590 | IC50 = 40.54 µM | MIF tautomerase inhibitor Anti-neuroinflammation Neuroprotection |
|
| 11 | IC50 = 11.95 µM | MIF tautomerase inhibitor Anti-neuroinflammation |
|
| 4-IPP | IC50 = 0.2-0.5 μM | Covalent MIF inhibitor Anti-inflammation |
PRO1, TYR36, HIS62, VAL106, PHE113, TYR95, ASN97 |
| PAANIB-1 | IC50 = 0.28 μM | MIF nuclease inhibitor Prevention of neurodegeneration |
LEU61 ASN72 |